Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edgewise Therapeutics (EWTX), Gilead Sciences (GILD)...

Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Gilead Sciences (GILD) and Codexis (CDXS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC), Gilead Sciences (GILD) ...

Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OrthoPediatrics (KIDS), Gilead Sciences (GILD) and S...

Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)

Stocks ended the week higher as investors looked past policy noise and leaned back into risk assets. The Dow Jones Industrial Average (DJIA) rose 0...

The Week That Was, The Week Ahead: Macro and Markets, June 14

Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences today and set a price target of $170.00. According to TipRanks, Sye...

Mizuho Securities Remains a Buy on Gilead Sciences (GILD)

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Gilead Sciences has launched a Phase 2 study titled “A Phase 2, Open L...

Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA) and Gilead Scienc...

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD)

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $160.00. The compa...

Gilead Sciences (GILD) Gets a Buy from Bernstein

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Jazz Pharmaceuticals (JAZZ) ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD), Hims & Hers Health (HIMS) ...

Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Hims & Hers Health (HIMS) and Nurix Therapeutics (NRIX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and Moo...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. The IDEAL Phase 3 study, officially titled “IDEAL: A 52-week, Double-b...

Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardent Health Partners, Inc. (ARDT), Lemaitre Vascul...

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Lemaitre Vascular (LMAT) and Gilead Sciences (GILD)

Scotiabank analyst Louise Chen maintained a Buy rating on Gilead Sciences today and set a price target of $177.00. Chen covers the Healthcare secto...

Scotiabank Sticks to Its Buy Rating for Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Gilead Sciences (GILD) ...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $122.00. According ...

Gilead Sciences (GILD) Gets a Hold from RBC Capital

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. The Gilead Sciences (GILD) study, “Pioneering Research to Optimize Pre...

Gilead’s Lenacapavir PrEP Study: Real-World Data That Could Reshape the HIV Prevention Market

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and Alkermes (ALKS) with bull...

Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)

Analysts are intrested in these 5 stocks: ( ($SM) ), ( ($CASY) ), ( ($GILD) ), ( ($D) ) and ( ($PODD) ). Here is a breakdown of their recent


SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts

Jefferies analyst Akash Tewari maintained a Buy rating on Gilead Sciences today and set a price target of $180.00. Tewari covers the Healthcare sec...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$123.76	-1.35%	14.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$123.76	-1.3%	14.35M
3
4
5
6

GILD

GILD

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel